Zeevi Adriana, Girnita Alin, Duquesnoy Rene
Department of Pathology, Thomas E Starzl, Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Immunol Res. 2006;36(1-3):255-64. doi: 10.1385/IR:36:1:255.
The clinical relevance of humoral allosensitization has gained a lot of attention in the last few years. An increasing number of studies have demonstrated adverse graft survival in patients who have either preformed or post-transplant-developed anti-HLA antibodies. The detection of HLA antibodies and the specificity analysis have evolved over time from primarily cell-based to solid-phase methods, including the availability of single-HLA antigen preparations. These technological advances combined with a better understanding of the epitope structure of HLA antigens have provided a more efficient, structurally based strategy to determine HLA compatibility. In conclusion, these emerging approaches can be reliably used to predict crossmatch results in highly sensitized patients and also to monitor the development of clinically relevant anti-HLA antibody after transplantation.
在过去几年中，体液同种致敏的临床相关性受到了广泛关注。越来越多的研究表明，无论是移植前就已存在还是移植后产生抗HLA抗体的患者，其移植物存活情况不佳。随着时间的推移，HLA抗体的检测及特异性分析已从主要基于细胞的方法发展为固相方法，包括单HLA抗原制剂的应用。这些技术进步，再加上对HLA抗原表位结构的更深入了解，为确定HLA相容性提供了一种更高效的、基于结构的策略。总之，这些新出现的方法可可靠地用于预测高度致敏患者的交叉配型结果，也可用于监测移植后临床相关抗HLA抗体的产生情况。
